Which promising biotech stocks should investors be tracking as we roll towards ? The three small-cap biotechs I cover below all present very interesting investment opportunities. Of course, investing in biotechs involves a degree of risk as the share price is so closely correlated with success in key clinical trials. This makes it even more important to research biotechs thoroughly before making any notable portfolio additions.
In this case we used the powerful Nasdaq Smart Portfolio stock screener to find only stocks with significant Street support over the last three months.
We then scanned through the generated results to find stocks that also reveal impressive upside potential. Shares in Heron Therapeutics look set to soar in In comparison to rival offerings, HTX has the advantage of simultaneously targeting both pain and inflammation. And the picture from the Street is only positive. In the last three months, Heron has received an impressive seven back-to-back buy ratings. One of the more recent ratings comes from four-star Northland Securities analyst Carl Byrnes.
At the same time, Byrnes believes that HTX can become the best-in-class therapy for postoperative pain management. The drug provides sustained relief for the first 72 hours and minimizes the need for highly-addictive opioids.
Shares halved in May after Ardelyx reported topline results for a Phase 2 trial of its gut-drug tenapanor. While the results reached the desired efficacy, it still failed to beat rival drugs in the treatment of irritable bowel syndrome with constipation IBS-C. Now however, the outlook has flipped following much more encouraging results from a Phase 3 trial. As a result, analysts are confident that the stock can double in the next 12 months.
In fact, Chiang suggests that the drug has a significant opportunity in not one, but two markets. We believe both of these segments are sizeable market opportunities. Overall, TipRanks shows that four analysts have published buy ratings on the stock in the last three months. Iovance is a key biotech in the field of novel cancer immunotherapies. It is developing unique treatments based on tumor infiltrating lymphocytes TIL.
Investors will be keenly listening out for updates on the ongoing Phase 2 trial of lead product, LN, a personalized cell therapy for advanced melanoma which already boasts FDA fast-track status. The current study involves 60 advanced melanoma patients who have already failed prior systemic therapies.
Breidenbach sums up his bullish investment thesis on the company thus: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Enter up to 25 symbols separated by commas or spaces in the text box below.
This article appears in: Most Popular Highest Rated. Altran Group acquires Aricent and creates the Why Ekso Bionics Dropped as Much as View All Highest Rated. Research Brokers before you trade. Visit our Forex Broker Center.
If you have any questions or encounter any issues in changing your default settings, please email isfeedback nasdaq.More...